Clinical trial NCT03926754: Beta 3 Agonist Treatment in Heart Failure-2
Official title: Beta 3 Agonist Treatment in Heart Failure-2
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Heart Failure With Reduced Ejection Fraction NYHA Class III-IV
Lead sponsor: Rigshospitalet, Denmark
Sponsor class: OTHER
Collaborators: name: Bispebjerg-Frederiksberg Hospital, Denmark
name: Hillerød hospital, Denmark
name: Herlev Hospital
name: Hvidovre University Hospital
name: Bornholm Hospital, Denmark
name: Royal North Shore Hospital
First posted: 2019-04-24
Enrollment: 56
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Objective: The objective of the study is to assess the structural and functional cardiac effects of treatment with the beta 3 AR agonist Mirabegron in patients with moderate to severe chronic heart failure (LVEF\<35%, NYHA III-IV).

The study is a randomized, placebo-controlled, double-blinded trial in two phases with two hypotheses:

Chronic study - study A: Long-term treatment (3 months) with the β3 adrenergic receptor agonist Mirabegron is beneficial in patients with moderate to severe human heart failure

Invasive study - Study B: Administration of Mirabegron in patients with heart failure leads to an immediate increase in cardiac output at a constant or reduced left ventricular filling pressure during submaximal exercise

Specific aims

1. Determine safety of administration of Mirabegron to patients with moderate to severe heart failure.
2. Determine if treatment with Mirabegron for 3 months induces beneficial cardiac structural remodelling in patients with moderate to severe heart failure. In an open-label follow-up to determine the effects of Mirabegron after an extended duration (a total of 12 months).
3. Determine if Mirabegron improves symptoms and exercise capacity as indicated by questionnaires and 6 min walk test in patients with moderate to severe heart failure.
4. Determine effects of Mirabegron on cardiac conduction, repolarisation and rhythms and arrhythmias in patients with moderate to severe heart failure.
5. Determine effects of Mirabegron on circulating biomarkers in patients with moderate to severe heart failure.
6. Determine the immediate and short term haemodynamic effects of Mirabron as measured by CT and invasively.


Eligibility criteria: Inclusion Criteria:

1. Stable heart failure NYHA class III-IV on ischemic or non-ischemic basis
2. Left ventricular ejection fraction (LVEF) \< 35% as assessed by cardiac CT
3. NT proBNP \> 1000 pg/ml
4. On optimised evidence-based pharmacological HF treatment stable ≥2 weeks with no current plan for changing HF therapy. The therapy must include a beta-blocker.
5. No change in diuretics ≤1 week
6. No admittances to hospital for treatment with intravenously administered positive inotropic agents ≤ 4 weeks.
7. \>18 years

Exclusion Criteria:

1. Acute myocardial infarction (AMI) or revascularisation \< 3 month ago
2. Uncorrected significant primary obstructive valve disease
3. Planned major surgery including cardiac revascularisation
4. Hemodynamically significant obstructive cardiomyopathy
5. Acute myocarditis or constrictive pericarditis
6. Clinically significant hepatic (transaminases or bilirubin x 3 above upper reference level) or renal (GFR\< 30 ml/min/1,73 m2) diseases
7. Heart failure due to uncorrected thyroid disease
8. Cardiac mechanical support
9. \< 6 months after CRT
10. Uncontrolled hypotension (defined as symptomatic systolic blood pressure \< 80 mmHg) - or hypertension (defined as systolic at 180 mmHg or above and/or diastolic blood pressure at 110 mmHg or below)
11. Unable to give informed consent
12. Reduced compliance
13. All women of child bearing potential will be required to use adequate contraception
14. Pregnant or lactating women
15. Treatment with a tricyclic antidepressant or CYP2D6 substrates other than beta-blockers or treatment with digoxin.
16. Known allergy to iodine containing contrast
17. Estimated GFR \< 30 ml/min/1.73 m2
18. Congenital or drug induced QT prolongation

Primary outcomes:
measure: Increase in left ventricular ejection fraction as measured by computed tomography
timeFrame: 3 months
measure: Change in invasive hemodynamics assesses by right heart catherization
timeFrame: At 3 hours and at 1 week
Secondary outcomes:
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: Rigshospitalet
Study officials:
References:
citation: Bundgaard H, Axelsson A, Hartvig Thomsen J, Sorgaard M, Kofoed KF, Hasselbalch R, Fry NA, Valeur N, Boesgaard S, Gustafsson F, Kober L, Iversen K, Rasmussen HH. The first-in-man randomized trial of a beta3 adrenoceptor agonist in chronic heart failure: the BEAT-HF trial. Eur J Heart Fail. 2017 Apr;19(4):566-575. doi: 10.1002/ejhf.714. Epub 2016 Dec 18.